Redirecting T cells to glypican-3 with 28.41BB.ζ and 28.ζ-41BBL CARs for hepatocellular carcinoma treatment
Sign Up to like & getrecommendations! Published in 2017 at "Protein & Cell"
DOI: 10.1007/s13238-017-0489-0
Abstract: T cells genetically engineered to express CARs specific for CD19 have shown breakthrough clinical successes in patients with B-cell lymphoid malignancies in recent years (Grupp SA et al., 2013; Kalos M et al., 2011; Maude… read more here.
Keywords: gpc3 car; car cells; gpc3; cell ... See more keywords